Lexeo Therapeutics (LXEO) COO sells 1,304 shares, retains 136K stake

Q: What insider transaction did LXEO report for Jose Manuel Otero?

Lexeo Therapeutics (LXEO) reported that COO Jose Manuel Otero sold 1,304 shares of common stock. The shares were sold on August 18, 2026 primarily to cover tax obligations from a restricted stock unit release.

Q: At what price were the LXEO shares sold by Jose Manuel Otero?

Jose Manuel Otero’s 1,304 LXEO shares were sold at a weighted average price of $4.9571 per share. The transaction was executed in multiple trades at prices ranging from $4.94 to $5.01 .

Q: How many LXEO shares does Jose Manuel Otero hold after this transaction?

After the sale, Jose Manuel Otero directly holds 136,178 shares of Lexeo Therapeutics common stock. This total includes 97,026 Restricted Stock Units (RSUs) , which represent additional equity that will typically settle in shares upon vesting.

Q: Why did Jose Manuel Otero sell LXEO shares in this Form 4 filing?

The filing states the sale of 1,304 LXEO shares was made to cover tax obligations triggered by the release of restricted stock units. This indicates the transaction was tax-related rather than a discretionary portfolio sale.

Q: Was the LXEO insider sale by Jose Manuel Otero a single trade or multiple trades?

The 1,304-share LXEO sale was executed in multiple trades at prices between $4.94 and $5.01 . The reported $4.9571 figure is the weighted average sale price across these individual executions.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Lexeo Therapeutics, Inc. (LXEO) reported that Chief Operating Officer Jose Manuel Otero sold 1,304 shares of common stock on August 18, 2026 at a weighted average price of $4.9571 per share. The sale was made to cover tax obligations arising from the release of restricted stock units. Following this transaction, Otero directly holds 136,178 shares of Lexeo common stock, including 97,026 Restricted Stock Units.

Insider Trade Summary

Net Seller: 1,304 shares

Net Sell 1 txn

Insider Otero Jose Manuel

Role Chief Operating Officer

Sold 1,304 shs ($6K)

Type	Security	Shares	Price	Value
Sale	Common Stock ^{F1, F2, F3}	1,304	$4.9571	$6K

Holdings After Transaction: Common Stock — 136,178 shares (Direct)

Footnotes (3)

F1. Represents a sale to cover tax obligations on the release of restricted stock units ("RSUs").
F2. This transaction was executed in multiple trades at prices ranging from $4.94 to $5.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3. Includes 97,026 Restricted Stock Units.

Key Figures

Shares sold: 1,304 shares Weighted average sale price: $4.9571 per share Trade price range: $4.94 to $5.01 per share +2 more

5 metrics

Shares sold 1,304 shares Common stock sale by COO Jose Manuel Otero on August 18, 2026

Weighted average sale price $4.9571 per share Weighted average price for 1,304 LXEO shares sold

Trade price range $4.94 to $5.01 per share Price range of multiple trades comprising the reported sale

Shares held after transaction 136,178 shares Direct holdings of Jose Manuel Otero after the reported sale

Restricted Stock Units included 97,026 Restricted Stock Units Portion of Otero’s post-transaction holdings represented by RSUs

Key Terms

Restricted Stock Units, weighted average sale price, open market or private transaction

3 terms

Restricted Stock Units financial

"Includes 97,026 Restricted Stock Units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average sale price financial

"The price reported above reflects the weighted average sale price."

open market or private transaction financial

"Sale in open market or private transaction"

FAQ

What insider transaction did LXEO report for Jose Manuel Otero?

Lexeo Therapeutics (LXEO) reported that COO Jose Manuel Otero sold 1,304 shares of common stock. The shares were sold on August 18, 2026 primarily to cover tax obligations from a restricted stock unit release.

At what price were the LXEO shares sold by Jose Manuel Otero?

Jose Manuel Otero’s 1,304 LXEO shares were sold at a weighted average price of $4.9571 per share. The transaction was executed in multiple trades at prices ranging from $4.94 to $5.01.

How many LXEO shares does Jose Manuel Otero hold after this transaction?

After the sale, Jose Manuel Otero directly holds 136,178 shares of Lexeo Therapeutics common stock. This total includes 97,026 Restricted Stock Units (RSUs), which represent additional equity that will typically settle in shares upon vesting.

Why did Jose Manuel Otero sell LXEO shares in this Form 4 filing?

The filing states the sale of 1,304 LXEO shares was made to cover tax obligations triggered by the release of restricted stock units. This indicates the transaction was tax-related rather than a discretionary portfolio sale.

Was the LXEO insider sale by Jose Manuel Otero a single trade or multiple trades?

The 1,304-share LXEO sale was executed in multiple trades at prices between $4.94 and $5.01. The reported $4.9571 figure is the weighted average sale price across these individual executions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/19/2026 - 05:00 PM Accepted by SEC EDGAR 08/19/2026 - 05:00 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Otero Jose Manuel

(Last)

(First)

(Middle)

C/O LEXEO THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, FLOOR 6

(Street)

NEW YORK

10010

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Lexeo Therapeutics, Inc. [ LXEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/18/2026		S⁽¹⁾		1,304	D	$4.9571⁽²⁾	136,178⁽³⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents a sale to cover tax obligations on the release of restricted stock units ("RSUs").

2. This transaction was executed in multiple trades at prices ranging from $4.94 to $5.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

3. Includes 97,026 Restricted Stock Units.

	/s/ Youjin Choi, Attorney-in-Fact	08/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR